A Phase 1 interventional study of Intervention 1: Mustard Gel and Intervention 2 : Mineral Trioxide Aggregate (MTA) in Dental Pulp Exposure, sponsored by Dr Nida Farooq. Not yet recruiting. Open to participants aged 6 Years to 8 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Dr Nida Farooq · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this clinical trial is to compare two materials to treat baby molars with deep cavities. When the cavity is very deep and reaches the nerve of a baby tooth, dentist perform a treatment called "Pulpotomy". This means removing the damaged part of the nerve and placing medicament on healthy part to help tooth heal and stay pain-free until it falls out naturally. The standard medicine used today is Mineral Trioxide Aggregate (MTA) for treating baby molars that have deep cavities. It works well but is expensive and can darken the tooth. The study is testing a new medicine called Mustard Gel , made from black mustard seeds and may help heal the tooth. Mustard has natural healing and germ-fighting properties.This trial will help to compare Mustard Gel with MTA to see if the agent works to treat pulpitis.
Children aged 6-8 years who need a pulpotomy procedure on a baby molar will be selected. During this procedure, infected part of the pulp tissue will be removed and medicament will be placed over the remaining healthy pulp.
Selected participants will be put into one of the two groups by chance:
31 studies on the registry are indexed under Dental Pulp Exposure; 5 are open to participants now.
This study's planned enrollment of 72 is above the median of 53 across 29 interventional studies indexed under Dental Pulp Exposure.
Browse Dental Pulp Exposure studies →This is the only study on the registry with Dr Nida Farooq as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary molars will undergo pulpotomy followed by application of Mustard Gel in as pulpotomy medicament. After the removal of coronal pulp tissue and hemostasis the mustard gel will be applied directly over the radicular pulp stumps under aseptic conditions followed by the placement of suitable base and permanent filling material to seal tooth. Clinical and radiographic follow up will be done at 1 week, 1 month, and 3 months.
Drug: Intervention 1: Mustard Gel
MTA will be used as pulpotomy agent in decidoud molars following standard clinical procedure after coronal pulp amputation. The treated tooth will be restored with appropriate base and final restoration. Clinical and radiographic follow up will be done at 1 week, 1 month and 3 months.
Drug: Intervention 2 : Mineral Trioxide Aggregate (MTA)
Drug pages: MechlorethamineStudies of MechlorethamineMechlorethamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Mustard GasStudies of Mustard GasMustard Gas pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Gel obtained from Brassica nigra (Black Mustard) seeds will be used as pulpotomy medicament in primary molars placed over pulp stumps after coronal pulp amputation. Approximately 1mm of mustard gel will be applied and tooth will be sealed with permanent filling material.
MTA will be mixed according to manufacturer's instructions and placed over the pulp stumps to a thickness of 1-2 mm using an amalgam carrier. It will be compressed gently with damp cotton pellet, the restored with glass-ionomer cement.
Clinical and Radiographic success rate of Pulpotomy
The proportion of the teeth treated with pulpotomy that show clinical and radiographic success. Clinical success rate is defined as absence of pain, swelling, abscess or pathological mobility. Radiographic success is defined as absence of internal/external root resorption, furcal/periapical radiolucency or widened PDL space. assessment will be done using clinical examination and periapical radiographs.
Time frame: At 1 week, 1 month, 3 months post treatment.
No study locations are listed for this record.
Start is estimated for Apr 2026; primary completion for Jun 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mechlorethamine · Mustard Gas